Abstract
Radiation therapy (RT) remains a cornerstone in the treatment of malignant tumors (MT) of the oral cavity and pharynx and is recognized as one of the key modalities in modern oncology. However, the administration of RT in these regions poses considerable challenges, primarily due to the high incidence of severe acute and late radiation-induced reactions affecting the oropharyngeal mucosa. In some cases, these adverse effects render the completion of the full RT course unfeasible. Effective pharmacological management of such radiation-induced complications is critical to improving the quality of life of oropharyngeal cancer patients, enhancing treatment compliance, and remains a significant issue in current radiation oncology. This article reports a clinical case involving a 65-year-old patient diagnosed with oropharyngeal cancer staged cT4acN2cM0 (stage IVA), who underwent RT. To mitigate acute radiation mucositis, a medical device containing a combination of hyaluronic acid, chondroitin sulfate, and the bioadhesive agent Poloxamer 407 was utilized. Despite the radiation doses and mean exposure levels to critical structures being associated with a high risk of grade 2 acute radiation-induced reactions, the patient achieved effective management of mucosal toxicity in the oral cavity, pharynx, and esophagus. This allowed for the uninterrupted completion of the prescribed RT course. Keywords: remote radiation therapy, radiotherapy, tumors of the head and neck, tumors of the oral cavity, tumors of the pharynx, tumors of the oropharynx. For citation: Ilyin M.A. Chemoradiation of a patient with locally advanced oropharyngeal cancer during oral administration of a combined product, containing hyaluronic acid, chondroitin sulfate and Poloxamer 407 bioadhesive substance. RMJ. 2024;10:44–48. DOI: 10.32364/2225-2282-2024-10-8
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call